Destiny Pharma PLC Appointment of Joint Broker (4997I)
March 22 2018 - 3:02AM
UK Regulatory
TIDMDEST
RNS Number : 4997I
Destiny Pharma PLC
22 March 2018
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY
THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER
THE EU MARKET ABUSE REGULATION (596/2014). UPON THE PUBLICATION OF
THE ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS
INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.
Destiny Pharma plc
("Destiny Pharma" or "the Company")
Appointment of Joint Broker
Brighton, United Kingdom - 22 March 2018 - Destiny Pharma (AIM:
DEST), a clinical stage biotechnology company focused on the
development of novel anti-microbial drugs, which address the global
problem of anti-microbial resistance (AMR), today announces the
appointment of finnCap Ltd as joint broker to the Company with
immediate effect. Cantor Fitzgerald Europe remains nominated
adviser and joint broker to the Company.
For further information, please contact:
Destiny Pharma plc
Neil Clark, CEO
Simon Sacerdoti, CFO
pressoffice@destinypharma.com
+44 (0)1273 704 440
FTI Consulting
Simon Conway / Victoria Foster Mitchell
destinypharma@fticonsulting.com
+44 (0) 20 3727 1000
Cantor Fitzgerald Europe (Nominated Adviser and Joint
Broker)
Philip Davies / Will Goode, Corporate Finance
Andrew Keith, Healthcare Equity Sales
+44 (0)20 7894 7000
finnCap Ltd (Joint Broker)
Geoff Nash /Kate Bannatyne, Corporate Finance
Alice Lane, Corporate Broking
+44 (0)20 7220 0500
About Destiny Pharma
Destiny Pharma is an established, clinical stage, innovative
biotechnology company focused on the development of novel medicines
that represent a new approach to the treatment of infectious
disease. These potential new medicines are being developed to
address the need for new drugs for the prevention and treatment of
life-threatening infections caused by antibiotic-resistant
bacteria, often referred to as "superbugs". Tackling anti-microbial
resistance has become a global imperative recognised by the WHO and
the United Nations, as well as the G7 and the G20 countries. For
further information, please visit
https://www.destinypharma.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
APPQFLFLVXFBBBQ
(END) Dow Jones Newswires
March 22, 2018 03:02 ET (07:02 GMT)
Destiny Pharma (LSE:DEST)
Historical Stock Chart
From Apr 2024 to May 2024
Destiny Pharma (LSE:DEST)
Historical Stock Chart
From May 2023 to May 2024